| [1] |
中华医学会感染病学分会, GRADE中国中心. 中国乙型肝炎病毒母婴传播防治指南(2019年版).中华传染病杂志, 2019, 37:388-396.
|
| [2] |
周乙华,李彤,庄辉. 对《中国乙型肝炎病毒母婴传播防治指南(2019年版)》的商榷. 肝脏,2020,25:2-4.
|
| [3] |
刘锦锋, 陈天艳, 陈耀龙, 等. 对《对<中国乙型肝炎病毒母婴传播防治指南(2019年版)>的商榷》一文的回复. 肝脏,2020,25:4-6.
|
| [4] |
咸建春, 孙鸿展, 肖丽, 等. 对《 感染乙型肝炎病毒的育龄女性临床管理共识》 的一些拙见.中国病毒病杂志,2019,9:327-332.
|
| [5] |
Zhou YH. Occult hepatitis B virus infection, or occult cross-contamination, in children of HBsAg-positive mothers. J Viral Hepat, 2016,23:830.
|
| [6] |
中华医学会妇产科学分会产科学组. 乙型肝炎病毒母婴传播预防临床指南(第1版). 中华妇产科杂志, 2013, 48:151-154.
|
| [7] |
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. J Hepatol, 2017, 67:370-398.
|
| [8] |
Terrault NA, Lok ASF, McMahon BJ, et al. Update on Prevention, Diagnosis, And Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology, 2018, 67:1560-1599.
|
| [9] |
Zhang L, Gui XE, Wang B, et al. Serological positive markers of hepatitis B virus in femoral venous blood or umbilical cord blood should not be evidence of in-utero infection among neonates. BMC Infect Dis,2016,16:408.
|
| [10] |
Liu J, Xu B, Chen T, et al. Presence of hepatitis B virus markers in umbilical cord blood: Exposure to or infection with the virus? Dig Liver Dis, 2019, 51:864-869.
|
| [11] |
中华医学会感染病学分会,中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版). 肝脏,2019,24:1335-1356.
|
| [12] |
Zhang H, Pan CQ, Pang Q, et al. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology, 2014, 60:468-476.
|
| [13] |
Jourdain G, Ngo-Giang-Huong N, Harrison L, et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N Engl J Med, 2018, 378:911-923.
|
| [14] |
Hu Y, Xu C, Xu B, et al. Safety and efficacy of telbivudine in late pregnancy to prevent mother-to-child transmission of hepatitis B virus: A multicenter prospective cohort study. J Viral Hepat, 2018, 25:429-437.
|
| [15] |
Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med, 2016, 374:2324-2334.
|
| [16] |
Pan CQ, Yi W, Liu M, et al. Lamivudine therapy during the second vs the third trimester for preventing transmission of chronic hepatitis B. J Viral Hepat, 2017, 24:246-252.
|
| [17] |
Yi W, Pan CQ, Hao J, et al. Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers. J Hepatol, 2014, 60:523-529.
|
| [18] |
Han Z, Zhang Y, Bai X, et al. Mother-to-child transmission of hepatitis B virus after amniocentesis: A retrospective matched cohort study. Prenat Diagn, 2019, 39:431-440.
|
| [19] |
Yin Y, Wu L, Zhang J, et al. Identification of risk factors associated with immunoprophylaxis failure to prevent the vertical transmission of hepatitis B virus. J Infect, 2013, 66:447-452.
|
| [20] |
Zhu YY, Mao YZ, Wu WL, et al. Does hepatitis B virus prenatal transmission result in postnatal immunoprophylaxis failure? Clin Vaccine Immunol, 2010, 17:1836-1841.
|
| [21] |
冯静, 李洁, 刘景丽, 等. 羊膜腔穿刺对乙型肝炎病毒母婴传播的影响. 中华围产医学杂志, 2015, 18:823-827.
|
